Emergent Biosolutions Inc. (EBS) — SEC Filings
Emergent Biosolutions Inc. (EBS) — 50 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 35 8-K, 6 10-Q, 4 SC 13G/A.
View Emergent Biosolutions Inc. on SEC EDGAR
Overview
Emergent Biosolutions Inc. (EBS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: Emergent BioSolutions Inc. filed an 8-K on December 12, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. No specific financial figures or material events beyond the filing itself are deta
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 48 neutral, 2 mixed. The dominant filing sentiment for Emergent Biosolutions Inc. is neutral.
Filing Type Overview
Emergent Biosolutions Inc. (EBS) has filed 35 8-K, 6 10-Q, 1 DEF 14A, 1 10-K, 1 S-1/A, 1 SC 13G, 1 S-1, 4 SC 13G/A with the SEC between Apr 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of EBS's 42 recent filings, 0 were flagged as high-risk, 28 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $594.2M |
| Net Income | $107.2M |
| EPS | $1.99 |
| Debt-to-Equity | 1.51 |
| Cash Position | $245.5M |
| Operating Margin | 21.5% |
| Total Assets | $1,461.0M |
| Total Debt | $663.1M |
Key Executives
- Miller Member
- Papa Member
- Richard S. Lindahl
- Matthew C. Franker
- Julie M. Plyler
- Robert L. Johnson
- Dr. David M. Glick
- Douglas L. Schantz
- Robert J. Recchia
- Karen E. Holcom
- Paul E. Rogers
- Robert G. Kramer
- Robert G. (Bob) Kramer
- Paul F. McKinney
Industry Context
Emergent BioSolutions operates in the biopharmaceutical sector, focusing on public health threats and emerging diseases. The industry is characterized by long development cycles, high R&D costs, and significant reliance on government contracts for specialized products like medical countermeasures. Competition exists from both large pharmaceutical companies and smaller biotech firms, with regulatory approvals and manufacturing capabilities being key differentiators.
Top Tags
8-K (8) · disclosure (8) · sec-filing (6) · financial-condition (5) · material-agreement (5) · financials (5) · regulatory-filing (4) · results-of-operations (4) · financial-reporting (4) · 8-k (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $107.2M | for nine months ended September 30, 2025, compared to a $159.3 million net loss in 2024 |
| Total Revenues | $594.2M | for nine months ended September 30, 2025, down from $848.9 million in 2024 |
| Cash and Cash Equivalents | $245.5M | as of September 30, 2025, up from $99.5 million at December 31, 2024 |
| Total Operating Expenses | $466.2M | for nine months ended September 30, 2025, down from $948.1 million in 2024 |
| Product and Services Sales, Net | $561.4M | for nine months ended September 30, 2025, down from $824.3 million in 2024 |
| Net Cash Provided by Operating Activities | $92.9M | for nine months ended September 30, 2025, compared to $138.6 million in 2024 |
| Net Cash Provided by Investing Activities | $73.3M | for nine months ended September 30, 2025, compared to $96.6 million in 2024 |
| Net Cash Used in Financing Activities | $22.7M | for nine months ended September 30, 2025, compared to $190.5 million in 2024 |
| Common Stock Outstanding | 52,519,964 | as of October 22, 2025 |
| Basic Earnings Per Share | $0.96 | for the three months ended September 30, 2025, compared to $2.16 in 2024 |
| SEC File Number | 001-33137 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 14-1902018 | Tax identification number for the company. |
| Q2 2025 Net Loss | $10.5M | Improved from $30.2M net loss in Q2 2024 |
| Q2 2025 Revenue | $150.3M | Decreased 9.3% from $165.8M in Q2 2024 |
| YTD 2025 Net Loss | $25.7M | Improved from $60.1M net loss in YTD 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Emergent Biosolutions Inc. (EBS)?
Emergent Biosolutions Inc. has 50 recent SEC filings from Apr 2024 to Dec 2025, including 35 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EBS filings?
Across 50 filings, the sentiment breakdown is: 48 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Emergent Biosolutions Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Emergent Biosolutions Inc. (EBS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Emergent Biosolutions Inc.?
Key financial highlights from Emergent Biosolutions Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EBS?
The investment thesis for EBS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Emergent Biosolutions Inc.?
Key executives identified across Emergent Biosolutions Inc.'s filings include Miller Member, Papa Member, Richard S. Lindahl, Matthew C. Franker, Julie M. Plyler and 9 others.
What are the main risk factors for Emergent Biosolutions Inc. stock?
Of EBS's 42 assessed filings, 0 were flagged high-risk, 28 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Emergent Biosolutions Inc.?
Forward guidance and predictions for Emergent Biosolutions Inc. are extracted from SEC filings as they are enriched.